share_log
Breakings ·  Jun 13 21:02
Vyne Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel Bd2-Selective Bet Inhibitor Vyn202
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment